Literature DB >> 12639654

Preoperative cardiopulmonary risk assessment as predictor of early noncancer and overall mortality after radical prostatectomy.

Michael Froehner1, Rainer Koch, Rainer Litz, Sven Oehlschlaeger, Birgit Noack, Andreas Manseck, D Michael Albrecht, Manfred P Wirth.   

Abstract

OBJECTIVES: To evaluate the capability of the preoperative cardiopulmonary risk assessment to predict early noncancer and overall mortality after radical prostatectomy for clinically localized prostate cancer.
METHODS: In 444 consecutive radical prostatectomy patients, the American Society of Anesthesiologists Physical Status classification and the presence of cardiac insufficiency (New York Heart Association classification), angina pectoris (Canadian Cardiovascular Society classification), diabetes, hypertension, history of thromboembolism, and chronic obstructive or restrictive pulmonary disease were assessed. Kaplan-Meier time-event curves and Mantel-Haenszel hazard ratios were estimated for noncancer (other deaths were censored) and overall mortality. Cox proportional hazard models were used to analyze possible combined effects of risk factors.
RESULTS: During an average follow-up of 4.7 years, 36 patients died: 15 of noncancer causes, 14 of prostate cancer, 6 of other cancers, and 1 in a car accident. The comorbidity scores for American Society of Anesthesiologists Physical Status classification, New York Heart Association classification, and Canadian Cardiovascular Society classification and combinations between the latter two scores were significantly associated with early noncancer mortality in a dose-response pattern. Furthermore, patients with chronic obstructive pulmonary disease were at increased risk. The association with overall mortality was less strong.
CONCLUSIONS: The preoperative cardiopulmonary risk assessment may be used as a predictor of early noncancer and overall mortality after radical prostatectomy and should be evaluated further as a source of prognostic information in surgical oncology.

Entities:  

Mesh:

Year:  2003        PMID: 12639654     DOI: 10.1016/s0090-4295(02)02250-1

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  6 in total

Review 1.  [Chemotherapy in the elderly].

Authors:  G Lümmen; H Rübben
Journal:  Urologe A       Date:  2003-11       Impact factor: 0.639

2.  [The significance of comorbidity and age in radical prostatectomy].

Authors:  M Wirth; M Fröhner
Journal:  Urologe A       Date:  2004-08       Impact factor: 0.639

Review 3.  Diabetes and cancer (2): evaluating the impact of diabetes on mortality in patients with cancer.

Authors:  A G Renehan; H-C Yeh; J A Johnson; S H Wild; E A M Gale; H Møller
Journal:  Diabetologia       Date:  2012-04-04       Impact factor: 10.122

Review 4.  Does pre-existing diabetes affect prostate cancer prognosis? A systematic review.

Authors:  C F Snyder; K B Stein; B B Barone; K S Peairs; H-C Yeh; R L Derr; A C Wolff; M A Carducci; F L Brancati
Journal:  Prostate Cancer Prostatic Dis       Date:  2009-09-01       Impact factor: 5.554

Review 5.  Long-term all-cause mortality in cancer patients with preexisting diabetes mellitus: a systematic review and meta-analysis.

Authors:  Bethany B Barone; Hsin-Chieh Yeh; Claire F Snyder; Kimberly S Peairs; Kelly B Stein; Rachel L Derr; Antonio C Wolff; Frederick L Brancati
Journal:  JAMA       Date:  2008-12-17       Impact factor: 56.272

Review 6.  Diabetes and mortality in patients with prostate cancer: a meta-analysis.

Authors:  Junga Lee; Edward Giovannucci; Justin Y Jeon
Journal:  Springerplus       Date:  2016-09-13
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.